Skip to content
Screener

Shares (Diluted) at other companies

Eli Lilly logo
Eli LillyLLY
893.7M-0.7%
Amgen logo
AmgenAMGN
544M+0.6%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
165.4M-9.3%
Arrowhead Research logo
Arrowhead ResearchARWR
142.4M+5.9%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
61.3M+8.9%
Regenxbio logo
RegenxbioRGNX
53M+3.0%

Other financials

Income statement

See full
Revenue$214.0M+28.1%
Operating income-$75.0M+30.6%
Net income-$92.0M+20.0%
EPS (diluted)-$0.90+23.1%

Balance sheet

See full
Cash & equivalents$125.0M-29.0%
Total debt$36.0M-10.8%
Total equity-$291.0M-293%
Total assets$1.3B-3.2%

Cash flow

See full
Operating cash flow-$97.0M+11.0%
CapEx$1.0M-66.7%
Free cash flow-$98.0M+12.5%

Valuation

See full
Market cap$2.55B-5.8%
P/S3.6×-0.9×

Profitability

See full
Gross margin97.2%
Operating margin-73.6%-7.3pp
Net margin-81.7%-4.9pp
FCF margin-68.2%-1.7pp

Returns & leverage

See full
Return on equity-325.6%+36.9pp
Debt / equity3.7×
Current ratio1.7×-0.7×

Where this comes from

Reported directly by Ultragenyx Pharmaceutical in its filing.

Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.

The source filing: Ultragenyx Pharmaceutical’s 10-Q, filed August 5, 2026.

Filed
Aug 4, 2026, 8:00 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-333233
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Interest income561113
Non-cash interest expense on liabilities for sales of future royalties(22)(14)(43)(28)
Other income1212
Loss before income taxes(91)(114)(275)(264)
Provision for income taxes(1)(1)(2)(2)
Net loss$(92)$(115)$(277)$(266)
Net loss per share, basic and diluted$(0.90)$(1.17)$(2.73)$(2.73)
Shares used in computing net loss per share, basic and diluted101.998.5101.397.4

Item 1. Financial Statements

FAQ

What is Ultragenyx Pharmaceutical's shares (diluted)?
Ultragenyx Pharmaceutical (RARE) reported shares (diluted) of 101.9M in Q2 2026.
How has Ultragenyx Pharmaceutical's shares (diluted) changed year-over-year?
Ultragenyx Pharmaceutical's shares (diluted) increased by 3.5% year-over-year, from 98.5M to 101.9M.
What is the long-term trend for Ultragenyx Pharmaceutical's shares (diluted)?
Over 4 years (2021 to 2025), Ultragenyx Pharmaceutical's shares (diluted) has grown at a 9.8% compound annual growth rate (CAGR), from 270.4M to 393.2M.
What does shares (diluted) mean?
The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.

Ask your AI about Ultragenyx Pharmaceutical's shares (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude